RNAC

Cartesian Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 8/10
  • Momentum↓ 2/10
Cartesian Therapeutics sales and earnings growth
RNAC Growth
Good
  • Revenue Y/Y↓ -97.72%
  • EPS Y/Y↑ 97.30%
  • FCF Y/Y↓ -41.60%
Cartesian Therapeutics gross and profit margin trends
RNAC Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -4638.60%
  • ROIC↓ -27.00%
Cartesian Therapeutics net debt vs free cash flow
RNAC Risk
Great
  • Debt / Equity↓ -0.4
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Cartesian Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗